InVitria launches Optibumin® 25, the first recombinant 25% rHSA for closed-system use, enabling safer, scalable ...

Optibumin® 25 – a 25% recombinant human serum albumin (rHSA) solution developed ... For decades, plasma-derived HSA has presented regulatory and supply chain challenges, including batch ...

InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only recombinant human serum albumin ...

Optibumin® 25 is the first recombinant 25% human serum albumin for closed-system biomanufacturing, offering consistency, sterility, and GMP compliance. For decades, plasma-derived HSA has ...

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced ...

TNX-1700 is in preclinical development for gastric and colorectal cancers ...

Tonix is developing human TFF2-human serum albumin (hTFF2-HAS ... Tonix is developing TNX-1700 (rTFF2-HSA) for the treatment of gastric and colon cancers under a license from Columbia University.

Tonix is developing human TFF2-human serum albumin (hTFF2-HAS ... Tonix is developing TNX-1700 (rTFF2-HSA) for the treatment of gastric and colon cancers under a license from Columbia University.

A new study from researchers at the University of Sydney highlights the potential of inhalable cannabidiol (CBD) powder using ...